VELA Investment Management LLC Cuts Stock Position in Bruker Corporation $BRKR

VELA Investment Management LLC trimmed its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 45.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 68,000 shares of the medical research company’s stock after selling 55,591 shares during the period. VELA Investment Management LLC’s holdings in Bruker were worth $2,209,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Universal Beteiligungs und Servicegesellschaft mbH lifted its stake in shares of Bruker by 3.8% during the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 573,164 shares of the medical research company’s stock worth $18,622,000 after purchasing an additional 21,011 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Bruker by 727.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,100 shares of the medical research company’s stock valued at $166,000 after buying an additional 4,484 shares during the period. SG Americas Securities LLC raised its holdings in shares of Bruker by 199.8% during the 3rd quarter. SG Americas Securities LLC now owns 42,293 shares of the medical research company’s stock valued at $1,374,000 after buying an additional 28,184 shares during the period. Spire Wealth Management lifted its position in Bruker by 85.3% during the 3rd quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock worth $47,000 after acquiring an additional 665 shares in the last quarter. Finally, Park Avenue Securities LLC purchased a new position in Bruker in the 3rd quarter worth approximately $238,000. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, VP Mark Munch sold 7,000 shares of Bruker stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $55.00, for a total value of $385,000.00. Following the completion of the transaction, the vice president directly owned 128,443 shares of the company’s stock, valued at approximately $7,064,365. The trade was a 5.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director John A. Ornell sold 6,233 shares of the stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $39.00, for a total transaction of $243,087.00. Following the sale, the director owned 35,212 shares in the company, valued at approximately $1,373,268. This trade represents a 15.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 15,233 shares of company stock valued at $726,487 over the last ninety days. Company insiders own 27.30% of the company’s stock.

Bruker Trading Up 4.2%

Shares of NASDAQ BRKR opened at $51.95 on Thursday. The company has a quick ratio of 0.91, a current ratio of 1.85 and a debt-to-equity ratio of 0.81. The stock’s 50 day moving average price is $47.70 and its two-hundred day moving average price is $40.20. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $61.01. The stock has a market capitalization of $7.89 billion, a P/E ratio of -324.69, a PEG ratio of 6.55 and a beta of 1.17.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12. The business had revenue of $860.50 million during the quarter, compared to the consensus estimate of $847.40 million. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The business’s quarterly revenue was down .5% on a year-over-year basis. During the same period in the previous year, the business earned $0.60 EPS. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, analysts anticipate that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 2nd. Shareholders of record on Monday, December 8th were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend was Monday, December 8th. Bruker’s dividend payout ratio is -125.00%.

Wall Street Analyst Weigh In

BRKR has been the topic of a number of recent research reports. Guggenheim boosted their target price on shares of Bruker from $45.00 to $53.00 and gave the stock a “buy” rating in a research report on Monday, January 5th. Zacks Research upgraded shares of Bruker from a “strong sell” rating to a “hold” rating in a report on Monday, December 8th. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a research note on Monday, December 29th. JPMorgan Chase & Co. increased their price target on Bruker from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Finally, Bank of America lifted their price objective on Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.36.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.